Biosimilar Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Product (Recombinant Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins), By Technology, By Application, By Region and Competition

Global Biosimilar Contract Manufacturing Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing prevalence of various chronic diseases. Additionally, the increasing availability of cancer biosimilars with lowered prices and affordable treatment, along with the growing adoption of cost-effective healthcare systems across the globe, has increased the demand for biosimilar contract manufacturing. Additionally, the growing geriatric population across the globe, susceptible to different kinds of chronic diseases, is further expected to increase the demand for biosimilar contract manufacturing, thereby fuelling market growth through 2028. Besides, growing awareness of new therapy related to oncology and other chronic diseases is further expected to support the biosimilar contract manufacturing market during the forecast period. Furthermore, the impending patent expiry of biological products alongside the launch of new biosimilars and increasing early entry of new players, are further expected to increase the demand for biosimilar contract manufacturing, thereby supporting the market growth. A total of 17 cancer or cancer-related biosimilar products have been approved by the US Food and Drug Administration since 2015.

The growing Prevalence of Chronic Disease is Propelling the Market’s Growth

The increasing incidence of diabetes and easy availability of biosimilars at lower costs over branded insulins are expected to drive the demand for insulin biosimilars’ adoption, thereby fuelling the market growth in the forecast period. The increasing demand for monoclonal antibodies is one of the major factors expected to boost market growth. Furthermore, recombinant glycosylated protein biosimilars are used for the treatment of blood disorders, cancers, and infectious diseases. The most commonly occurring autoimmune disorders that can be treated by biosimilars are polyarticular spondylitis, plaque psoriasis, Crohn’s disease, and arthritis. These conditions are commonly treated with biosimilars such as adalimumab and etanercept, making them the most preferred therapy for autoimmune disorders. The high rate of these diseases is expected to increase the demand for biosimilars, thus boosting market growth in the forecast period. In 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans have type 1 diabetes, including about 244,000 children and adolescents.

Increasing Contract Research Organizations Are Driving the Market’s Growth

The demand for contract manufacturing and services has been rapidly rising in the pharmaceutical market over the last few years. Some of the important Clinical Research Organizations (CROs) are IQVIA, Syneos Health, ICON, and Parexel. Contract research and manufacturing organizations help pharmaceutical companies in risk reduction, reduction in expenditures, aid in complex drug manufacturing processes, and shorten lead times. Additionally, the growing demand for novel drug discovery and the increasing number of clinical trials pertaining to research and development in the pharma industry are likely to enhance the CRO market share in the future. Spain accounts for the sixth largest market for subsequent entry biologics in the European Union. The regulatory approval of biosimilars is likely to improve its demand in manufacturing and hence is expected to promote the market’s growth.

Market Segmentation

The global biosimilar contract manufacturing market can be segmented by product, technology, application, and by region. Based on the product, the market can be divided into Recombinant Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins. Based on technology, the market can be divided into Mammalian v/s non-Mammalian. Based on application, the market can be grouped into Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United Kingdom dominated the global biosimilar contract manufacturing market on account of the growing demand for lower-cost therapy for the treatment of chronic disease.

Market Players

Catalent, Inc., Boehringer Ingelheim GmbH, Alcami Corporation, Inc., Almac Group, Lonza Group AG, Biocon Limited, Avid Bioservice, Inc, Rentschler Biopharma SE, Fujifilm Kyowa Kirin Biologics Co., Ltd., WuXi Biologics, Inc. are some of the leading players operating in the Global Biosimilar Contract Manufacturing Market.

Recent Development

• For instance, in August 2021, Samsung Biologics announced that it plans to invest USD 205 billion and hire more people to improve its CDMO business in biosimilar, and other things in the coming years. It will benefit several Samsung businesses, including Samsung Bioepis, which deals with biosimilars, and Samsung Biologics, which handles contract manufacturing.
• For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Report Scope:

In this report, global biosimilar contract manufacturing market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilar Contract Manufacturing Market, By Product:

• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins

Biosimilar Contract Manufacturing Market, By Technology:

• Mammalian
• Non-Mammalian

Biosimilar Contract Manufacturing Market, By Application:

• Oncology
• Blood Disorders
• Growth Hormonal Deficiency
• Chronic & Autoimmune Disorders
• Rheumatoid Arthritis
• Others

Biosimilar Contract Manufacturing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Biosimilar Contract Manufacturing Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.


This product will be delivered within 1-3 business days.